Role of Endoplasmic Reticulum Stress in Diabetic Neuropathy
Neuropathy affects up to 50% of people with diabetes and is a major risk factor for foot ulceration and amputation (1). The etiology is multifactorial, and currently there is no satisfactory treatment except maintenance of good glycemic control (2), thereby highlighting the importance of identifying novel therapeutic targets.
The endoplasmic reticulum (ER) forms a membranous network throughout the cytosol and is contiguous with the outer nuclear membrane. The ER has three major functions: 1) synthesis, folding, and maturation of proteins; 2) Ca2+ storage; and 3) lipid biosynthesis. The ER provides a Ca2+-rich oxidizing environment for the formation of disulphide bonds and accurate protein folding. This process is controlled by Ca2+-dependent molecular chaperones and protein-folding enzymes such as glucose-regulated protein 78/immunoglobulin binding protein (GRP78/BiP), glucose-regulated protein 94, and protein disulfide isomerase. Folding to produce the native protein conformation is a complex, energy-requiring process. This process may be disrupted in pathological conditions, resulting in a buildup of misfolded and potentially toxic proteins that give rise to ER stress. Homeostatic responses to ER stress comprise the unfolded protein response (UPR). The UPR consists of signaling systems (Fig. 1) that are based on three transmembrane stress sensors. 1) The first is PKR-like eukaryotic initiation factor 2A kinase (PERK). Normally, PERK is bound to the chaperone GRP78/BiP, but as unfolded proteins accumulate GRP78/BiP dissociates, thereby activating PERK, which then phosphorylates eukaryotic initiation factor 2α, ultimately leading to general inhibition of protein translation and synthesis. 2) GRP78/BiP also dissociates from inositol-requiring enzyme 1, which mediates mRNA splicing reaction for the transcription factor X box-binding protein 1. In turn, this participates in the increased production of ER chaperones and CAAT/enhancer-binding protein homologous protein (CHOP), which contributes to ER-dependent degradative processes, including cell death if ER stress is severe and prolonged. 3) Activating transcription factor 6 translocates to the Golgi apparatus, producing another transcription factor, activating transcription factor 6N, which stimulates chaperone and protein folding enzyme expression. In addition, the UPR activates proinflammatory pathways based on nuclear factor-κB (NF-κB), p38 mitogen-activated protein kinase (p38MAPK), and c-Jun N-terminal kinase (JNK) signaling. ER stress can profoundly affect cellular signaling and viability and plays a key role in neurodegenerative diseases, ischemia-reperfusion injury, cardiovascular diseases, cancer, and diabetes/obesity (3–5). Within the context of diabetes complications, ER stress has been linked to nephropathy (6), retinopathy (7), endothelial dysfunction (8), and cognitive decline (9).
In this issue of Diabetes, Lupachyk et al. (10) examined the role of ER stress in the development of peripheral neuropathy in streptozotocin-induced diabetic rodents. Two experimental models were used. The first used rats with 12 weeks’ diabetes duration. In these experiments, groups of diabetic and nondiabetic rats were treated with one of two structurally dissimilar chemical chaperones (trimethylamine oxide [TMAO] or 4-phenylbutyric acid [PBA]) to counteract ER stress by promoting normal protein folding (11). Markers of the UPR were examined in sciatic nerve by Western blot. Results showed that diabetes caused upregulation of phospho-PERK, phospho-eukaryotic initiation factor 2α, inositol-requiring enzyme 1, CHOP, GRP78/BiP, and ER oxidase 1α. These results were largely suppressed by TMAO, and no effects were observed in nondiabetic rats. There were similar findings for spinal cord and for treatment with PBA. These data establish the presence of ER stress in neural tissue of diabetic rats. Cellular localization by immunohistochemistry would provide further important information: the data demonstrated that chaperone treatment is an effective strategy and is in line with the literature in other disease models (12) including diabetic nephropathy (13). Importantly, there was no obvious action of the drugs on glycemic control.
Blocking ER stress with chaperones partially protected against the development of decrements in sciatic motor nerve conduction velocity and completely prevented digital nerve sensory nerve conduction velocity deficits in diabetic rats. Behavioral measures of reflex foot withdrawal to potentially noxious stimuli showed reduced thermal and mechanical responses (hypoalgesia), and enhanced sensitivity to touch (tactile allodynia) with diabetes. These abnormal responses were approximately halved by both treatments. Additional dose-response information would be required to assess whether maximal treatment benefits were being achieved in these experiments. In addition, although TMAO prevented intraepidemal nerve fiber loss in diabetic rats, the behavioral results suggest that although distal dying-back of nerves was attenuated, the fibers might not have maintained completely normal function.
The second set of experiments compared neuropathic effects in CHOP−/− mice with those in their wild-type counterparts. Twelve weeks of diabetes doubled CHOP levels in sciatic nerve of wild-type mice, whereas CHOP was undetectable in the transgenic mice. There was a marked attenuation of motor and sensory nerve conduction velocity deficits, thermal hypoalgesia, and intraepidermal nerve fiber loss in the diabetic CHOP−/− mice. Intriguingly, diabetes-induced mechanical hypoalgesia and tactile allodynia remained at similar levels in both CHOP−/− and wild-type mice. This differs from the positive effects of chaperone treatment in rats on these measures, plausibly because different aspects of ER stress and the UPR were targeted.
Interestingly, nerve tissue markers of oxidative/nitrosative stress were elevated by diabetes in both rats and mice and were also markedly attenuated by TMAO treatment or CHOP knockout. This is consistent with findings for diabetic nephropathy (13), in which PBA treatment reduced markers of oxidative stress in kidney, serum, and urine. Upregulation of folding capacity as part of the UPR would increase oxidative stress; hydrogen peroxide is a by-product of S-S bond formation during protein folding (14). As oxidative/nitrosative stress can trigger ER stress, there is an element of positive feedback that could produce a self-reinforcing disease cycle.
Lupachyk et al. (10) have established ER stress as a contributor to diabetic neuropathy and highlight that various elements of the UPR are potentially novel therapeutic targets. Further research is needed to clarify their relative clinical and scientific importance. Moreover, the relevance of the “alarm response” of the UPR, with its accompanying activation of proinflammatory pathways based on NF-κB, p38MAPK, and JNK, and the role of proapoptotic and necrotic cell changes also need to be assessed. NF-κB cascade and p38MAPK inhibition correct measures of diabetic neuropathy in rats (15,16). Given the role of ER stress in cardiovascular disease (5,8) and the contribution of reduced nerve blood flow and endoneurial hypoxia to the pathogenesis of diabetic neuropathy (2,17), further investigation is required to assess whether UPR modulation improves nerve perfusion. Finally, experiments were preventive, and there was incomplete protection of nerve function; it would be of practical interest to ascertain whether ER stress inhibition could reverse established neuropathic changes.
No potential conflicts of interest relevant to this article were reported.
The author thanks Prof. Mary A. Cotter, University of Aberdeen, for thoughtful comments on the manuscript.
See accompanying original article, p. 944.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.